Abbott
Prices for Abbott's Norvir (generic name Ritonavir) as a Standalone Product in 2010
Submitted by Anne Mira Guha on 10. August 2010 - 14:09KEI Research Note 2010:4
August 12, 2010
Anne Mira Guha
1. Introduction
FOIA document: In 2007, US Ambassador Ralph Boyce was pleased that Abbott withdrew life saving drugs from market in Thailand
Submitted by James Love on 6. March 2010 - 17:26In 2007, Thailand was involved in a dispute over the granting of compulsory licenses on medicines, including the patents used for Kaletra, an Abbott drug used in the treatment of AIDS. Kaletra is the brand name for a fixed dose combination of lopinavir and ritonavir (LPV/r) -- two drugs invented at Abbott on an NIH grant. In 2007, LPV/r was the preferred combination for protease inhibitor regimes used to treat AIDS.
Abbott recently sought compulsory license in US patent dispute
Sunday, 29 April 2007
(When the shoe was on the other foot, Abbott asked for a compulsory license, while criticizing Thailand for issuing compulsory licenses)
On the 12th of January 2007, Abbott Laboratories lost a bid in a U.S. District Court (the Western District of Wisconsin) for a compulsory license on a patent held by Innogenetics, Inc. that a judge and jury said Abbott infringed to manufacture and sell Hepatitis C virus (HCV) genotyping test kits.
Abbott (ABT): Select Joint Ventures, Partnerships, and Alliances
Monday, 10 September 2007
Select Joint Ventures, Partnerships, and Alliances with Big Pharma
Abbott and Millennium - In March 2001 Abbott and Millennium formed a strategic alliance for the discovery, development and commercialization of drugs and diagnostics in the area of obesity and diabetes. This alliance also provided for non-exclusive technology transfer and the co-development of technology tools. According to Millennium's 2001 SEC filing, the deal i
U.S. DoS Cable: ABBOTT AND GOB REACH DEAL TO AVOID COMPULSORY LICENSE
Submitted by Staff on 12. October 2005 - 22:00R 131556Z – October 13, 2005
FM AMEMBASSY BRAZILIA
TO SECSTATE WASHDC 3176
SUBJECT: ABBOTT AND GOB REACH DEAL TO AVOID COMPULSORY LICENSE
1. SENSITIVE BUT UNCLASSIFIED – PLEASE TREAT ACCORDINGLY
